Please login to the form below

Not currently logged in
Email:
Password:

Sanofi and Lexicon collaborate on new medication for diabetes

Plan to develop new investigational drugsotagliflozin

Sanofi

Sanofi and Lexicon Pharmaceuticals have agreed to collaborate in the development and commercialisation of sotagliflozin, an investigational new drug for diabetes.

Sotagliflozin is a new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), currently being studied in two pivotal phase III trials in type 1 diabetes. Phase III trials in type 2 diabetes are set to begin in 2016.

Pascale Witz, executive VP at Sanofi, said: “This agreement with Lexicon reinforces our commitment to helping people living with diabetes.

“Adding sotagliflozin to our portfolio, which includes medicines at virtually every stage of the treatment pathway, highlights our focus on providing a large and diverse set of therapeutic options for people with this disease.”

Sotagliflozin has previously shown encouraging results in phase II studies for type 1 diabetes, including reduction of blood sugar (HBA1C) improvement in glycaemic variability and reduced mealtime insulin dose compared with placebo.

Phase II studies exploring treatment in people with type 2 diabetes, including those with renal impairment, showed lowering of blood sugar (HbA1c), weight loss and blood pressure improvements. No increase in hypoglycaemic events was seen with sotagliflozin compared to background therapy.

Under the terms of the agreement, Lexicon will receive an upfront payment of $300m and is eligible to receive development, regulatory and sales milestone payments of up to $1.4bn.

Lexicon is also entitled to royalties on net sales of sotaglifozin and will share in the funding of a portion of the planned type 2 diabetes development costs over the next three years up to an aggregate of $100m.

Sanofi will be responsible for all clinical development and commercialisation activities of sotagliflozin for the treatment of type 2 diabetes around the world and will also be responsible for the commercialisation of sotagliflozin for type 1 diabetes outside the US.

Last week Sanofi also agreed to a collaboration with Korean-firm Hanmi to develop a portfolio of experimental, long-acting diabetes treatments.  

Article by
Nikhil Patel

9th November 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Triducive are a strategic healthcare consultancy who produce communications that have practical, dynamic application that encourage behaviour change because of the...

Latest intelligence

Top 10 benefits of virtual advisory boards
Why virtual advisory boards should be part of every brand's toolbox in the post-COVID new normal....
The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...